Department of Pharmaceutics and Pharmaceutical Technology, L. M. College of Pharmacy, Ahmedabad 380008, India.
Department of Pharmaceutical Chemistry, L. M. College of Pharmacy, Ahmedabad 380009, India.
Molecules. 2023 Mar 2;28(5):2332. doi: 10.3390/molecules28052332.
The COVID-19 pandemic has flared across every part of the globe and affected populations from different age groups differently. People aged from 40 to 80 years or older are at an increased risk of morbidity and mortality due to COVID-19. Therefore, there is an urgent requirement to develop therapeutics to decrease the risk of the disease in the aged population. Over the last few years, several prodrugs have demonstrated significant anti-SARS-CoV-2 effects in in vitro assays, animal models, and medical practice. Prodrugs are used to enhance drug delivery by improving pharmacokinetic parameters, decreasing toxicity, and attaining site specificity. This article discusses recently explored prodrugs such as remdesivir, molnupiravir, favipiravir, and 2-deoxy-D-glucose (2-DG) and their implications in the aged population, as well as investigating recent clinical trials.
新型冠状病毒肺炎疫情已在全球范围内蔓延，不同年龄组的人群受到的影响也不同。40 岁至 80 岁及以上人群因 COVID-19 而患重病和死亡的风险增加。因此，迫切需要开发治疗方法来降低老年人群的疾病风险。在过去的几年中，几种前药在体外检测、动物模型和医疗实践中均显示出显著的抗 SARS-CoV-2 作用。前药通过改善药代动力学参数、降低毒性和实现靶向性来增强药物递送。本文讨论了最近探索的前药，如瑞德西韦、莫努匹韦、法维拉韦和 2-脱氧-D-葡萄糖（2-DG）及其在老年人群中的应用，并研究了最近的临床试验。
